Physician profile
Jordan L Dutter
NPI 1730157835
$9,658.51
in general payments reported to CMS, 2019-2025
43 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $868 · 2021: $2,000 · 2022: $1,744 · 2023: $1,516 · 2024: $1,606 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,670.05 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,329.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,031.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $926.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $540.70 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $344.25 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $316.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $301.59 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $294.98 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Esperion Therapeutics, INC. | $280.49 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $261.91 | 2021-2023 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.24 | 2019-2025 | Jardiance |
| Pfizer INC. | $221.24 | 2019-2025 | |
| Mylan Specialty L.P. | $201.42 | 2019-2024 | Yupelri |
| Allergan, INC. | $188.62 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Dutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.